RXi licences ovarian cancer vax

Worcester, MA-based RXi Pharmaceuticals has licensed an ovarian cancer vaccine from The University of Texas MD Anderson Cancer Center and Henry M. Jackson Foundation for the Advancement of Military Medicine. The vaccine, which is designed to prevent the recurrence of endometrial adenocarcinomas, as well as ovarian and other gynecological cancers, targets folate binding protein-E39. FBP is overexpressed in ovarian and aggressive endometrial cancers, as well as breast, lung, colorectal and renal cell carcinomas. Phase I trials will begin later this year. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.